
COVID-19 antibodies persist, reduce reinfection risk for up to six months, study finds
The antibodies' ability to neutralize COVID-19 did not differ significantly over the six-month period.
The antibodies' ability to neutralize COVID-19 did not differ significantly over the six-month period.
It started as a quality assurance project by allergy residents. It became the most comprehensive venom allergy study in the country.
Effective treatments for ALS have eluded scientists for decades. A new examination of the immune system shows the appeal of personalized medicine for future care.
Researchers discover protein that regulates the gene expression for influential immune cells, paving a path for novel targets to treat inflammatory and allergic diseases.
Most asthma attacks in children are caused by viruses like the common cold. Michigan researchers get closer to explaining why.
A clinical trial for peanut allergy treatment has hit another milestone, with research suggesting graduated doses of peanut protein powder could help protect allergic children.